Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 12, pp 3728–3737 | Cite as

Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer

  • Yuichiro Okumura
  • Takehiro Noda
  • Hidetoshi Eguchi
  • Takuya Sakamoto
  • Yoshifumi Iwagami
  • Daisaku Yamada
  • Tadafumi Asaoka
  • Hiroshi Wada
  • Koichi Kawamoto
  • Kunihito Gotoh
  • Shogo Kobayashi
  • Yutaka Takeda
  • Masahiro Tanemura
  • Koji Umeshita
  • Yuichiro Doki
  • Masaki Mori
Translational Research and Biomarkers

Abstract

Background

The prognosis of biliary tract cancer (BTC) is unfavorable due to its chemoresistance. Hypoxia triggers epithelial-to-mesenchymal transition (EMT), which is closely related to drug resistance. In this study, we focused on the functional roles of procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), a hypoxia-induced gene, in BTC, and assessed the clinical significance of PLOD2.

Methods

The expression of PLOD2 under hypoxia was assessed in BTC cell lines. Gemcitabine-resistant (GR) BTC cell lines were transfected with small interfering RNA (siRNA) against PLOD2, and EMT markers and chemoresistance were evaluated. PLOD2 expression was also characterized using immunohistochemistry in BTC clinical specimens following resection. Patient survival was analyzed and the role of PLOD2 expression was examined.

Results

The expression of PLOD2 was induced by hypoxia in vitro and was upregulated in BTC-GR cell lines, which had low expression of epithelial markers and high expression of mesenchymal markers. Downregulation of PLOD2 by siRNA resulted in improved chemoresistance, recovery of epithelial markers, and reduction of mesenchymal markers. In the resected BTC samples, PLOD2 expression was significantly correlated with lymph node metastasis (p = 0.037) and stage (p = 0.001). Recurrence-free survival (p = 0.011) and overall survival (p < 0.001) rates were significantly lower in patients with high expression of PLOD2. PLOD2 expression was an independent prognostic factor for overall survival (p = 0.019).

Conclusions

The expression of PLOD2 influenced chemoresistance through EMT, and high expression of PLOD2 was a significant unfavorable prognostic factor in BTC patients. PLOD2 might be a potential therapeutic target for overcoming chemoresistance.

Notes

Acknowledgment

This work was supported in part by grants from Grant-in-Aid for Scientific Research of the Japan Society for the Promotion of Science (JSPS) [(C) 16K10572], Grant-in-Aid for Young Scientists of the JSPS [(B) 17K16543], and the Suzuken Memorial Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank the members of their laboratory for technical advice and helpful discussions.

Conflicts of interest

The authors declare no conflicts of interest associated with this manuscript.

Supplementary material

10434_2018_6670_MOESM1_ESM.docx (1.7 mb)
Supplementary material 1 (DOCX 50 kb)

References

  1. 1.
    Zhu AX, Hezel AF. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. Hepatology. 2011;53(2):695–704.CrossRefGoogle Scholar
  2. 2.
    Kim HJ, Kim CY, Hur YH, et al. Prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lymphovascular invasion. Surg Today. 2014;44(10):1879–86.CrossRefGoogle Scholar
  3. 3.
    Murakami S, Ajiki T, Okazaki T, et al. Factors affecting survival after resection of intrahepatic cholangiocarcinoma. Surg Today. 2014;44(10):1847–54.CrossRefGoogle Scholar
  4. 4.
    Kobayashi S, Nagano H, Marubashi S, et al. Treatment of borderline cases for curative resection of biliary tract cancer. J Surg Oncol. 2011;104(5):499–503.CrossRefGoogle Scholar
  5. 5.
    Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y, Mori M. Gastroenterological surgery in Japan: The past, the present and the future. Ann Gastroenterol Surg. 2017;1(1):5–10.CrossRefGoogle Scholar
  6. 6.
    Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis. Surg Today. 2017;47(2):182–92.CrossRefGoogle Scholar
  7. 7.
    Noda T, Shimoda M, Ortiz V, Sirica AE, Wands JR. Immunization with aspartate-beta-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma. Hepatology. 2012;55(1):86–97.CrossRefGoogle Scholar
  8. 8.
    Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study—the UK ABC-01 Study. Br J Cancer. 2009;101(4):621–7.CrossRefGoogle Scholar
  9. 9.
    Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–474.CrossRefGoogle Scholar
  10. 10.
    Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391–8.CrossRefGoogle Scholar
  11. 11.
    Ji RC. Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett. 2014;346(1):6–16.CrossRefGoogle Scholar
  12. 12.
    Liang D, Ma Y, Liu J, et al. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer. 2012;12:201.CrossRefGoogle Scholar
  13. 13.
    Zhang L, Huang G, Li X, et al. Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor-1α in hepatocellular carcinoma. BMC Cancer. 2013;13:108.CrossRefGoogle Scholar
  14. 14.
    Unwith S, Zhao H, Hennah L, Ma D. The potential role of HIF on tumour progression and dissemination. Int J Cancer. 2015;136(11):2491–503.CrossRefGoogle Scholar
  15. 15.
    Vanichapol T, Leelawat K, Hongeng S. Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signalregulated kinase signaling pathway. Mol Med Rep. 2015;12(3):3265–72.CrossRefGoogle Scholar
  16. 16.
    Zhan M, Wang H, Chen T, et al. NOX1 mediates chemoresistance via HIF1alpha/MDR1 pathway in gallbladder cancer. Biochem Biophys Res Commun. 2015;468(1–2):79–85.CrossRefGoogle Scholar
  17. 17.
    Ruotsalainen H, Vanhatupa S, Tampio M, Sipila L, Valtavaara M, Myllyla R. Complete genomic structure of mouse lysyl hydroxylase 2 and lysyl hydroxylase 3/collagen glucosyltransferase. Matrix Biol. 2001;20(2):137–46.CrossRefGoogle Scholar
  18. 18.
    Gilkes DM, Bajpai S, Wong CC, et al. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol Cancer Res. 2013;11(5):456–66.CrossRefGoogle Scholar
  19. 19.
    Eisinger-Mathason TS, Zhang M, Qiu Q, et al. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 2013;3(10):1190–205.CrossRefGoogle Scholar
  20. 20.
    van der Slot AJ, Zuurmond AM, Bardoel AF, et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem. 2003;278(42):40967–72.CrossRefGoogle Scholar
  21. 21.
    Wu J, Reinhardt DP, Batmunkh C, et al. Functional diversity of lysyl hydroxylase 2 in collagen synthesis of human dermal fibroblasts. Exp Cell Res. 2006;312(18):3485–94.CrossRefGoogle Scholar
  22. 22.
    Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002;5(1):19–33.CrossRefGoogle Scholar
  23. 23.
    Iwagami Y, Eguchi H, Nagano H, et al. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer. 2013;109(2):502–11.CrossRefGoogle Scholar
  24. 24.
    Yamada D, Kobayashi S, Wada H, et al. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer. 2013;49(7):1725–40.CrossRefGoogle Scholar
  25. 25.
    Hasegawa S, Eguchi H, Nagano H, et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer. 2014;111(8):1572–80.CrossRefGoogle Scholar
  26. 26.
    Mikamori M, Yamada D, Eguchi H, et al. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Sci Rep. 2017;7:42339.CrossRefGoogle Scholar
  27. 27.
    Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.CrossRefGoogle Scholar
  28. 28.
    Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–32.CrossRefGoogle Scholar
  29. 29.
    Erkan M, Kleeff J, Esposito I, et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene. 2005;24(27):4421–32.CrossRefGoogle Scholar
  30. 30.
    Song X, Liu X, Chi W, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol. 2006;58(6):776–84.CrossRefGoogle Scholar
  31. 31.
    Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A. 2014;111(50):E5429–38.CrossRefGoogle Scholar
  32. 32.
    Shukla SK, Purohit V, Mehla K, et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell. 2017;32(1):71–87.e7.CrossRefGoogle Scholar
  33. 33.
    Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, Semenza GL. Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem. 2013;288(15):10819-10829.CrossRefGoogle Scholar
  34. 34.
    Chen Y, Terajima M, Yang Y, et al. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest. 2015;125(3):1147–62.CrossRefGoogle Scholar
  35. 35.
    Miyamoto K, Seki N, Matsushita R, et al. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. Br J Cancer. 2016;115(3):354–63.CrossRefGoogle Scholar
  36. 36.
    Arao T, Yanagihara K, Takigahira M, et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer. 2006;118(2):483–9.CrossRefGoogle Scholar
  37. 37.
    Dong S, Nutt CL, Betensky RA, et al. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol. 2005;64(11):948–55.CrossRefGoogle Scholar
  38. 38.
    Noda T, Yamamoto H, Takemasa I, et al. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver Int. 2012;32(1):110–8.CrossRefGoogle Scholar
  39. 39.
    Song Y, Zheng S, Wang J, et al. Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma. Oncotarget. 2017;8(26):41947–62.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Xu F, Zhang J, Hu G, Liu L, Liang W. Hypoxia and TGF-beta1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation. Cancer Cell Int. 2017;17:54.CrossRefGoogle Scholar
  41. 41.
    Xu Y, Zhang L, Wei Y, et al. Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion. Oncotarget. 2017;8(14):23401–13.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.CrossRefGoogle Scholar
  43. 43.
    Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14(12):3629–37.CrossRefGoogle Scholar
  44. 44.
    Cannito S, Novo E, Compagnone A, et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis. 2008;29(12):2267–78.CrossRefGoogle Scholar
  45. 45.
    Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69(14):5820–8.CrossRefGoogle Scholar
  46. 46.
    Sakamoto T, Kobayashi S, Yamada D, et al. A histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer. PLoS One. 2016;11(1):e0145985.CrossRefGoogle Scholar
  47. 47.
    Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42.CrossRefGoogle Scholar
  48. 48.
    Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res. 2007;13(16):4769–76.CrossRefGoogle Scholar
  49. 49.
    Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415–28.CrossRefGoogle Scholar
  50. 50.
    Lluis JM, Buricchi F, Chiarugi P, Morales A, Fernandez-Checa JC. Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{kappa}B via c-SRC and oxidant-dependent cell death. Cancer Res. 2007;67(15):7368–77.CrossRefGoogle Scholar
  51. 51.
    Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472–6.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Yuichiro Okumura
    • 1
  • Takehiro Noda
    • 1
  • Hidetoshi Eguchi
    • 1
  • Takuya Sakamoto
    • 1
  • Yoshifumi Iwagami
    • 1
  • Daisaku Yamada
    • 1
  • Tadafumi Asaoka
    • 1
  • Hiroshi Wada
    • 1
  • Koichi Kawamoto
    • 1
  • Kunihito Gotoh
    • 1
  • Shogo Kobayashi
    • 1
  • Yutaka Takeda
    • 1
    • 2
  • Masahiro Tanemura
    • 1
    • 3
  • Koji Umeshita
    • 4
  • Yuichiro Doki
    • 1
  • Masaki Mori
    • 1
  1. 1.Department of Gastroenterological Surgery, Graduate School of MedicineOsaka UniversityOsakaJapan
  2. 2.Department of SurgeryKansai Rosai HospitalHyogoJapan
  3. 3.Department of SurgeryOsaka Police HospitalOsakaJapan
  4. 4.Division of Health Science, Graduate School of MedicineOsaka UniversityOsakaJapan

Personalised recommendations